This article was downloaded by: [Erciyes University] On: 23 December 2014, At: 22:01 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/gpss20

Hydrolytic Pathway of Glufosfamide, a New Phosphorylated Anticancer Agent

Marie-Caroline Aoust de Rouvèze $^{\rm a}$, Veronique Gilard $^{\rm a}$, Robert Martino $^{\rm a}$, Myriam Malet-Martino $^{\rm a}$ & Ulf Niemeyer $^{\rm b}$

 $^{\rm a}$ Biomedical NMR Group, IMRCP Laboratory , Université Paul Sabatier , 118, route de Narbonne, Toulouse, 31062, France

^b ASTA Medica AG , Franckfurt am Main, Germany Published online: 27 Oct 2010.

To cite this article: Marie-Caroline Aoust de Rouvèze, Veronique Gilard, Robert Martino, Myriam Malet-Martino & Ulf Niemeyer (2002) Hydrolytic Pathway of Glufosfamide, a New Phosphorylated Anticancer Agent, Phosphorus, Sulfur, and Silicon and the Related Elements, 177:6-7, 1735-1738, DOI: <u>10.1080/10426500212229</u>

To link to this article: http://dx.doi.org/10.1080/10426500212229

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions



HYDROLYTIC PATHWAY OF GLUFOSFAMIDE, A NEW PHOSPHORYLATED ANTICANCER AGENT

Marie-Caroline Aoust de Rouvèze,^a Veronique Gilard,^a Robert Martino,^a Myriam Malet-Martino,^a and Ulf Niemeyer^b Biomedical NMR Group, IMRCP Laboratory, Université Paul Sabatier, 118, route de Narbonne, 31062 Toulouse, France^a and ASTA Medica AG, Franckfurt am Main, Germany^b

> ³¹P NMR was used to demonstrate that glufosfamide is hydrolyzed into isophosphoramide mustard (IPM) with a half-life of about 25 h at 37°C and pH 7.4 in buffer as well as in human plasma. Through a cascade of reactions, IPM gives rise to three final products, dihydroxyIPM, phosphate ion, and phosphorylethanolamine, which is by far the major compound.

> Keywords: Glufosfamide; hydrolysis; isophosphoramide mustard; $^{31}\mathrm{P}\,\mathrm{NMR}$

INTRODUCTION

The anticancer drug glufosfamide (β -D-glucosylisophosphoramide mustard, glc-IPM) entered a clinical phase II trial in 1999. In this drug, IPM is coupled to the C1 of D-glucose in a β -glycosidic bond. Inside the cells, glc-IPM is mainly cleaved by glucosidases into D-glucose and IPM, but nonenzymatic hydrolysis could also contribute to its decay.¹ In this study, we investigated the time course of glc-IPM hydrolysis in buffered solutions at pH 7.4 and in human urine and plasma. Since the first stage of hydrolysis gives IPM, the chemical stability and the fate of IPM was also determined in the same conditions.

RESULTS AND DISCUSSION

³¹P NMR monitoring of the glc-IPM hydrolysis in cacodylate buffer at pH 7.4 shows that this compound ($\delta = 18.29$ ppm) gives IPM

Address correspondence to R. Martino. E-mail: martino@chimie.ups-tlse.fn

 $(\delta = 13.60 \text{ ppm})$ as the first intermediate, which is transformed into the monoaziridinyl derivative of IPM (monoAzIPM) ($\delta = 17.90 \text{ ppm}$) (Figure 1 and Scheme 1). This is in accordance with the fact that IPM gives also monoAzIPM at the same pH (data not shown). The rates of degradation of glc-IPM were $\approx 12-25$ -fold slower than those of IPM, depending on the temperature and medium (Table I). Up to now, the chemical stability of glc-IPM in any aqueous medium has not been reported. This study shows that its half-life ($t_{1/2}$) at 37°C was ≈ 1 day at pH 7.4 in buffer and plasma, slightly shorter (≈ 0.8 day) at pH 6 in urine, and slightly longer (≈ 1.2 day) at pH 8 in deproteinized plasma. The $t_{1/2}$ of IPM (Table I) were in agreement with the literature data (350 min at pH 7.0 and 25°C and in the range 49–84 min at pH 7.0–7.4 at 37°C).^{2.3}



SCHEME 1 Hydrolytic pathway of glc-IPM at pH 7.4.^{*a*} ^{*a*} All the compounds are represented in neutral form. Structures were characterized from one- and two-dimensional ¹H, ¹³C, and ³¹P NMR experiments. ^{*b*} δ are given at pH 7.4 in cacodylate buffer and 37°C. They are expressed in

 $^{o}\delta$ are given at pH 7.4 in cacodylate buffer and 37°C. They are expressed in ppm relative to 85% H₃PO₄ as external standard.



FIGURE 1 $\,$ ^{31}P NMR time course of the main hydrolytic products of glc-IPM at pH 7.4 (cacodylate buffer) and 37°C.

On the basis of the formation in time and the temporal patterns of the degradation compounds of glc-IPM at pH 7.4, its hydrolytic pathway can be summarized as illustrated in Scheme 1. IPM, monoAzIPM, and monohydroxyIPM (monoOHIPM) are intermediates. DihydroxyIPM (diOHIPM), phosphorylethanolamine (PEA), and phosphate ion (Pi) are the final products, PEA being the major one (Figure 1).

Identical hydrolytic profiles are observed for glc-IPM and IPM in urine and plasma; however, in plasma, additional ³¹P signals were

	Glc-IPM				IPM
Conditions	Т	(n) ^{<i>a</i>}	$\mathbf{t_{1/2}}^a$	(n) ^{<i>a</i>}	$\mathbf{t_{1/2}}^a$
Cacodylate buffer 7.4 Urine pH 6.0 ^b	25°C 37°C 37°C	(3) (4) (5)	$127 \pm 5 \text{ h}$ $25 \pm 3 \text{ h}$ $20 \pm 3 \text{ h}$	(3) (5) (6)	$373 \pm 33 ext{ min} \\ 65 \pm 12 ext{ min} \\ 98 \pm 14 ext{ min}$
Plasma pH 7.4 ^b Deproteinized plasma pH 8.3 ^b	37°C 37°C	(4) (1)	$24_{.5} \pm 1 \text{ h}$ 30 h	(5)	$107 \pm 16 \min$

TABLE I 31 P NMR-Derived Kinetic Data for Hydrolysis of glc-IPM and IPM

^{*a*}(n): number of experiments; $t_{1/2}$: half-life.

^bInitial pH can increase or decrease by 1–1.5 pH units, depending on the temperature, concentration of the solution, and duration of the experiments.

detected in the resonance area of IPM at 13.93 ppm (broad), 14.57 ppm, and 13.25 ppm. These δ suggest that these compounds correspond very probably to adducts of a nucleophile present in plasma with IPM via its aziridinyl derivatives.

In conclusion, this study demonstrated that glc-IPM is nonenzymatically hydrolyzed into IPM and determined the successive steps of its hydrolysis.

REFERENCES

- H. Seker, B. Bertram, A. Burkle, B. Kaina, J. Pohl, H. Koepsell, and M. Wiebler, Br. J. Cancer, 82, 629 (2000).
- [2] H. A. A. M. Dirven, L. Megens, M. J. Houdshoorn, M. A. Digemanse, B. van Ommen, and P. J. van Bladeren, *Chem. Res. Toxicol.*, 8, 979 (1995).
- [3] J. H. Boal, M. Williamson, V. L. Boyd, S. M. Ludeman, and W. Egan, J. Med. Chem., 32, 1768 (1989).